Welltower (WELL) Stock Forecast & Price Target

Welltower is underappreciated despite strong execution, and its outlook is supported by a diversified 2,950-property healthcare portfolio spanning senior housing, medical office, and skilled nursing/postacute care, including more than 900 properties in Canada and the United Kingdom. The company’s largest fundamental catalyst is the monetization of U.S. assets, which should simplify the story, reduce leverage, fund accretive clinic acquisitions and buybacks, and sharpen investor focus on its Canadian healthcare pure-play opportunity. Its Canadian clinic platform is already scaling through disciplined M&A, with 44 clinics and >300 providers added in 2025, while double-digit growth, margin expansion, and AI-enabled efficiency gains in WELLSTAR and WELL’s tech-enabled operations support continued FFO/AFFO growth.

Welltower is viewed negatively because its growth depends heavily on active M&A and a SHOP recovery that may prove too muted, while slower clinic deal activity, higher valuations, and integration missteps could limit earnings momentum. The company’s portfolio of 2,950 properties, including over 900 in Canada and the United Kingdom, also faces meaningful regulatory and reimbursement risk as governments confront rising deficits, debt, and pressure on healthcare funding. Although it trades at 0.9x EV/Revenue and 8.0x EV/EBITDA for C2027E, those discounts may not be enough if margins stay flat or decline, capital access tightens, or the market loses confidence in its ability to sustain growth at the current run-rate.